A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) Melero, I., Gangadhar, T. C., Kohrt, H., Segal, N., Logan, T., Urba, W., Hodi, F., Ott, P., Perez-Gracia, J., Wolchok, J. D., Shah, A., Kurland, J. F., Cohen, L. J., Levy, R., Wigginton, J. M., Goldberg, S. M. AMER SOC CLINICAL ONCOLOGY. 2013

View details for Web of Science ID 000335419605401